En fase III, randomiseret undersøgelse af adjuverende Dato-DXd i kombination med Rilvegostomig eller Rilvegostomig monoterapi versus standardbehandling, efter komplet tumorresektion, hos deltagere med trin I adenocarcinom NSCLC, som er ctDNA-positive eller har højrisiko patologiske egenskaber (TROPION-Lung12)
Et fase III, randomiseret, åbent, globalt studie af adjuverende Datopotamab Deruxtecan (Dato-DXd) i kombination med rilvegostomig eller rilvegostomig monoterapi versus standardbehandling, efter komplet tumorresektion, hos deltagere med trin I adenocarcinom lungekræft Hvem er ctDNA-positive eller har højrisiko patologiske egenskaber (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Barretos, Brasilien, 14784-057
- Research Site
-
Brasília, Brasilien, 70200-730
- Research Site
-
Florianópolis, Brasilien, 88034-000
- Research Site
-
São Paulo, Brasilien, 01323-903
- Research Site
-
Teresina, Brasilien, 64049-200
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3J4
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85724
- Research Site
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Research Site
-
Glendale, California, Forenede Stater, 91204
- Research Site
-
Los Angeles, California, Forenede Stater, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, Forenede Stater, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Research Site
-
St. Petersburg, Florida, Forenede Stater, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Research Site
-
Evanston, Illinois, Forenede Stater, 60201
- Research Site
-
Zion, Illinois, Forenede Stater, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Research Site
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Research Site
-
-
Montana
-
Billings, Montana, Forenede Stater, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, Forenede Stater, 13057
- Research Site
-
Mineola, New York, Forenede Stater, 11501
- Research Site
-
New York, New York, Forenede Stater, 10016
- Research Site
-
New York, New York, Forenede Stater, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- Research Site
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Research Site
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37920
- Research Site
-
Memphis, Tennessee, Forenede Stater, 38120
- Research Site
-
Nashville, Tennessee, Forenede Stater, 37203
- Research Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Research Site
-
Dallas, Texas, Forenede Stater, 75231
- Research Site
-
Houston, Texas, Forenede Stater, 77030
- Research Site
-
San Antonio, Texas, Forenede Stater, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8603
- Research Site
-
Chiba, Japan, 260-0877
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Fukuoka, Japan, 812-8582
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hiroshima, Japan, 734-8551
- Research Site
-
Hiroshima, Japan, 730-8518
- Research Site
-
Iwakuni-shi, Japan, 740-8510
- Research Site
-
Kashiwa, Japan, 277-8577
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Research Site
-
Kobe, Japan, 650-0017
- Research Site
-
Kumamoto, Japan, 860-8556
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Nagoya, Japan, 464-8681
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Research Site
-
Sapporo, Japan, 003-0804
- Research Site
-
Sendai, Japan, 980-8574
- Research Site
-
Sendai, Japan, 980-0873
- Research Site
-
Wakayama, Japan, 641-8510
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuala Lumpur, Malaysia, 50586
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
Taipei, Taiwan, 114
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Research Site
-
Bangkoknoi, Thailand, 10700
- Research Site
-
Banphaeo, Thailand, 74120
- Research Site
-
Dusit, Thailand, 10300
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Muang, Thailand, 50200
- Research Site
-
Muang, Thailand, 40002
- Research Site
-
Ratchathewi, Thailand, 10400
- Research Site
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06280
- Research Site
-
Ankara, Tyrkiet (Türkiye), 06010
- Research Site
-
Mersin, Tyrkiet (Türkiye), 33240
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Research Site
-
Hà Nội, Vietnam, 100000
- Research Site
-
Vinh, Vietnam, 460000
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
Andre navne:
Rilvegostomig IV (intravenous)
Andre navne:
|
|
Eksperimentel: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
Andre navne:
|
|
Aktiv komparator: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsramme: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsramme: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsramme: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Tidsramme: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
Tidsramme: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Tidsramme: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Tidsramme: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
Tidsramme: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- Ledende efterforsker: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Lungesygdomme
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karcinom
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Karcinom, ikke-småcellet lunge
- Adenocarcinom
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Alkaloider
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Indoler
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Vinca alkaloider
- Secologanin tryptamin alkaloider
- Indole alkaloider
- Indolizidiner
- Indolizines
- Platinforbindelser
- Vinorelbin
- Pemetrexed
- Etoposid
- Carboplatin
- Cisplatin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D926TC00001
- 2024-512195-35-00 (Registry Identifier: CTIS)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .